Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918783 · ClinicalTrials.gov registry record · Phase 1
Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer
A Phase 1 study of Peripheral Lung Tumor, sponsored by Impact Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05918783 is a Phase 1 study of Peripheral Lung Tumor that is actively recruiting participants, run by Impact Biotech. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05918783, a Phase 1 study of Peripheral Lung Tumor, is actively recruiting participants, sponsored by Impact Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure. Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05918783
The ClinicalTrials.gov registry entry for NCT05918783 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Impact Biotech, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Lung Tumor appearing as the primary indexed condition, and to 1 intervention - of which Padeliporfin Vascular Targeted Photodynamic (VTP) therapy is the first listed.
NCT05918783 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05918783 about?
NCT05918783 is a clinical study titled "Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer". Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days foll...
What is the current status of trial NCT05918783?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-05-28. Estimated completion is 2028-12-30.
What conditions does trial NCT05918783 study?
This clinical trial studies the following conditions: Peripheral Lung Tumor.
What interventions are being tested in trial NCT05918783?
The interventions under investigation include: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05918783?
This trial is sponsored by Impact Biotech, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918783 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.